- Alder Biopharmaceuticals has filed to raise up to $115M in an IPO on Nasdaq.
- The company develops anti-bodies for treating a range of conditions, and its pipeline includes Clazakizumab, which the the company is developing with Bristol-Myers Squipp for Rheumatoid Arthritis, and ALD403 for migraines.
- Alder posted losses of $20.6M in 2013.
- The company intends to trade under the ticker symbol ALDR.
- ETF: IPO
at Zacks.com (Nov 5, 2014)